Abstract | INTRODUCTION: METHODS: Improvement of CIPN was evaluated in adult patients, previously treated with (neo)adjuvant paclitaxel- ( breast cancer) or oxaliplatin-based ( colon cancer) therapies, receiving OnLife® for 3 months after completion of chemotherapy. The primary endpoint was to compare the severity of peripheral sensory neuropathy (PSN) and peripheral motor neuropathy (PMN) before and at the end of OnLife® treatment. Secondary endpoints included the assessment of patient-reported quality of life and CIPN symptoms as assessed by questionnaires. RESULTS: 146 patients (n = 75 breast cancer patients and n = 71 colon cancer patients) qualified for analysis; 31.1% and 37.5% of breast cancer patients had an improvement of PSN and PMN, respectively. In colon cancer patients, PSN and PMN improved in 16.9% and 20.0% of patients, respectively. According to patient-reported outcomes, 45.9% and 37.5% of patients with paclitaxel-induced PSN and PMN, and 23.9% and 22.0% of patients with oxaliplatin-induced PSN and PMN experienced a reduction of CIPN symptoms, respectively. CONCLUSION: OnLife® treatment confirmed to be beneficial in reducing CIPN severity and in limiting the progression of neuropathy, more markedly in paclitaxel-treated patients and also in patients with oxaliplatin-induced CIPN.
|
Authors | Matthias Zaiss, Jens Uhlig, Mark-Oliver Zahn, Thomas Decker, Helmar C Lehmann, Johanna Harde, Cathrin Hogrefe, Corinne Vannier, Norbert Marschner |
Journal | Oncology research and treatment
(Oncol Res Treat)
Vol. 44
Issue 11
Pg. 613-621
( 2021)
ISSN: 2296-5262 [Electronic] Switzerland |
PMID | 34496363
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2021 S. Karger AG, Basel. |
Chemical References |
- Antineoplastic Agents
- Oxaliplatin
|
Topics |
- Adult
- Antineoplastic Agents
(adverse effects)
- Colonic Neoplasms
(drug therapy)
- Humans
- Oxaliplatin
(adverse effects)
- Peripheral Nervous System Diseases
(chemically induced, diagnosis)
- Quality of Life
|